

GPI-16552, PARG inhibitor

Catalog	Unit
TBI1502-5MG	5 mg
TBI1502-25MG	25 mg

Product Details

Formal Name: N-bis-(3-Phenyl-propyl)-9-oxo-fluorene-2,7-diamide

Molecular Formula: C₃₃H₃₀N₂O₃ **Formula Weight:** 502.60 **CAS Number:** 443794-40-9

Purity: >98%

Formulation: powder

Solubility: Soluble in DMSO (up to 25 mg/ml) or in DMF (up to 25 mg/ml).

Storage: RT Stability: ≥ 2 years.

Applications

PARG inhibitor

Functions

A novel potent inhibitor of poly(ADP-ribose) glycohydrolase (PARG), IC50=1.7 μ M. Pre or post ischemia treatment (40 mg/kg) with GPI-16552 reduces brain infarct volumes in a rat model of cerebral ischemia. It modulates the inflammatory response to ischemia/reperfusion in a rat splanchnic artery occlusion model and reduces the degree of spinal cord inflammation and tissue injury after experimental spinal cord trauma. Synergizes with temozolomide in decreasing melanoma cell invasion and metastatic spreading in mice injected with B16 melanoma cells.

Application Procedures

First dissolved in DMSO (up to 25 mg/ml) or in DMF (up to 25 mg/ml), then diluted to aqueous buffer. Solutions in DMSO or DMF may be stored at -20° for up to 3 months.

For research use only.